» Articles » PMID: 35857944

Predictive Ability of Cardiopulmonary Exercise Test Parameters in Heart Failure Patients with Cardiac Resynchronization Therapy

Overview
Date 2022 Jul 20
PMID 35857944
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is evidence suggesting that a peak oxygen uptake (pVO2) cut-off of 10ml/kg/min provides a more precise risk stratification in cardiac resynchronization therapy (CRT) patients.

Objective: To compare the prognostic power of several cardiopulmonary exercise testing (CPET) parameters in this population and assess the discriminative ability of the guideline-recommended pVO2cut-off values.

Methods: Prospective evaluation of consecutive heart failure (HF) patients with left ventricular ejection fraction ≤40%. The primary endpoint was a composite of cardiac death and urgent heart transplantation (HT) in the first 24 follow-up months, and was analysed by several CPET parameters for the highest area under the curve (AUC) in the CRT group. A survival analysis was performed to evaluate the risk stratification provided by several different cut-offs. p values <0.05 were considered significant.

Results: A total of 450 HF patients, of which 114 had a CRT device. These patients had a higher baseline risk profile, but there was no difference regarding the primary outcome (13.2% vs 11.6%, p =0.660). End-tidal carbon dioxide pressure at anaerobic threshold (PETCO2AT)had the highest AUC value, which was significantly higher than that of pVO2in the CRT group (0.951 vs 0.778, p =0.046). The currently recommended pVO2cut-off provided accurate risk stratification in this setting (p <0.001), and the suggested cut-off value of 10 ml/min/kg did not improve risk discrimination in device patients (p =0.772).

Conclusion: PETCO2ATmay outperform pVO2's prognostic power for adverse events in CRT patients. The current guideline-recommended pVO2 cut-off can precisely risk-stratify this population.

Citing Articles

Prognostic value of cardiopulmonary exercise test in patients with acute myocardial infarction after percutaneous coronary intervention.

Li Z, Fan B, Wu Y, Rui H, Hu Y, Gu Y Sci Rep. 2024; 14(1):16331.

PMID: 39009689 PMC: 11251163. DOI: 10.1038/s41598-024-66963-5.


Cardiopulmonary Exercise Testing in the Age of New Heart Failure Therapies: Still a Powerful Tool?.

Garcia Bras P, Valentim Goncalves A, Reis J, Moreira R, Pereira-da-Silva T, Rio P Biomedicines. 2023; 11(8).

PMID: 37626705 PMC: 10452308. DOI: 10.3390/biomedicines11082208.


Measurement of PETCO2 at Anaerobic Threshold: A Best Prognostic Marker in Patients with Cardiac Resynchronization Therapy?.

da Silveira A, Pimentel M Arq Bras Cardiol. 2022; 119(3):424-425.

PMID: 36074375 PMC: 9438545. DOI: 10.36660/abc.20220477.